REGENERON PHARMACEUTICALS, INC.
REGNUS売上高
$14.3B
百万USD
営業利益
$3.6B
百万USD
純利益
$4.5B
百万USD
ROE
14.4%
最新FY
EPS
$41.48
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $2.5B | $1.1B | $10.09 |
| FY2021 | Q2 | $5.1B | $3.1B | $27.97 |
| FY2021 | Q3 | $3.5B | $1.6B | $14.33 |
| FY2021 | FY | $16.1B | $8.1B | $71.97 |
| FY2022 | Q1 | $3.0B | $974M | $8.61 |
| FY2022 | Q2 | $2.9B | $852M | $7.47 |
| FY2022 | Q3 | $2.9B | $1.3B | $11.66 |
| FY2022 | FY | $12.2B | $4.3B | $38.22 |
| FY2023 | Q1 | $3.2B | $818M | $7.17 |
| FY2023 | Q2 | $3.2B | $968M | $8.50 |
| FY2023 | Q3 | $3.4B | $1.0B | $8.89 |
| FY2023 | FY | $13.1B | $4.0B | $34.77 |
| FY2024 | Q1 | $3.1B | $722M | $6.27 |
| FY2024 | Q2 | $3.5B | $1.4B | $12.41 |
| FY2024 | Q3 | $3.7B | $1.3B | $11.54 |
| FY2024 | FY | $14.2B | $4.4B | $38.34 |
| FY2025 | Q1 | $3.0B | $809M | $7.27 |
| FY2025 | Q2 | $3.7B | $1.4B | $12.81 |
| FY2025 | Q3 | $3.8B | $1.5B | $13.62 |
| FY2025 | FY | $14.3B | $4.5B | $41.48 |
| FY2026 | Q1 | $3.6B | $727M | $6.75 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $6.7B | $7.9B | $8.5B | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| 営業利益 | $1.3B | $2.1B | $2.5B | $2.2B | $3.6B | $8.9B | $4.7B | $4.0B | $4.0B | $3.6B |
| 純利益 | $896M | $1.2B | $2.4B | $2.1B | $3.5B | $8.1B | $4.3B | $4.0B | $4.4B | $4.5B |
| 総資産 | $7.0B | $8.8B | $11.7B | $14.8B | $17.2B | $25.4B | $29.2B | $33.1B | $37.8B | $40.6B |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $4.4B | $6.1B | $8.8B | $11.1B | $11.0B | $18.8B | $22.7B | $26.0B | $29.4B | $31.3B |
| 営業CF | $1.5B | $1.3B | $2.2B | $2.4B | $2.6B | $7.1B | $5.0B | $4.6B | $4.4B | $5.0B |
| EPS | $7.70 | $10.34 | $21.29 | $18.46 | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |
| BPS | - | - | - | - | - | - | - | - | - | - |
| ROE | 20.1% | 19.5% | 27.9% | 19.1% | 31.9% | 43.0% | 19.1% | 15.2% | 15.0% | 14.4% |